Celgene Wins U.S. Approval for Psoriatic Arthritis Pill

Celgene Corp., the maker of the cancer drug Revlimid, won U.S. approval of a pill to treat psoriatic arthritis that may challenge injections that are among the best-selling drugs on the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.